Sort
39,280 grants matching “leukemia”
Development of first-in-class ST2 inhibitors for treating graft-versus-host disease
$650,311Chao-Yie Yang · University Of Tennessee Health Sci Ctr · R01 · FY2020 · HL
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology
$650,270Dong-Er Zhang · University Of California, San Diego · R01 · FY2019 · DK
Degrading therapeutically important kinases using small molecules
$650,235Nathanael Schiander Gray · Dana-Farber Cancer Inst · R01 · FY2019 · CA
Degrading therapeutically important kinases using small molecules
$650,235Nathanael Schiander Gray · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
$650,223Katharine C Hsu · Sloan-Kettering Inst Can Research · R01 · FY2021 · HL
TET2-mediated epitranscriptomic regulation in leukemia microenvironment
$650,167Jianjun Chen · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA
Therapeutic enzyme depletion of L-serine for cancer treatment
$650,029Everett Stone · University Of Texas At Austin · R01 · FY2023 · CA
Kansas City Clincal Oncology Program CCOP
$650,000Rakesh Gaur · Nci Community Oncology Research Program · U10 · FY2011 · CA
"A PHASE I STUDY INVESTIGATING THE SAFETY & EFFICACY OF DANVATIRSEN AS MONOTHERAPY FOLLOWED BY COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MDS & AML."
$650,000Aditi Shastri · Albert Einstein College Of Medicine · R01 · FY2023 · FD
"A PHASE I STUDY INVESTIGATING THE SAFETY & EFFICACY OF DANVATIRSEN AS MONOTHERAPY FOLLOWED BY COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MDS & AML."
$650,000Aditi Shastri · Albert Einstein College Of Medicine · R01 · FY2025 · FD
Nutrient Regulation of Cancer Cell Growth
$649,928Heather Christofk · University Of California Los Angeles · R01 · FY2025 · CA
Sensitive, Integrating Multi-Waveguide Biosensor
$649,919Cha-Mei Tang · Creatv Microtech, Inc. · R44 · FY2006 · CA
Who Cares For Older Breast Cancer Surivors And How Does It Affect Quality?
$649,884Jeanne Mandelblatt · Georgetown University · R01 · FY2009 · CA
Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescentsand Young Adults with Acute Lymphoblastic Leukemia
$649,823Julie Anna Wolfson · University Of Alabama At Birmingham · R01 · FY2023 · CA
Cross-species development and credentialing of pediatric AML models
$649,623Jeffrey Alan Magee · Washington University · R01 · FY2025 · CA
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC
$649,490Francis X McCormack · University Of Cincinnati · U01 · FY2020 · HL
Germline and Somatic Genomic Studies in CLL Minorities
$649,094Susan L Slager · Mayo Clinic Rochester · R01 · FY2023 · CA
Germline and Somatic Genomic Studies in CLL Minorities
$649,094Susan L Slager · Mayo Clinic Rochester · R01 · FY2022 · CA
Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer
$648,957Elizabeth Mary Swisher · University Of Washington · R01 · FY2025 · CA
Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer
$648,956Elizabeth Mary Swisher · University Of Washington · R01 · FY2023 · CA
MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication
$648,940Elizabeth Bouchard · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA
DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunity
$648,893Yi Zhang · Temple Univ Of The Commonwealth · R01 · FY2021 · HL
Promoting Treatment Adherence in Adolescent Leukemia
$648,827Dennis D Drotar · Cincinnati Childrens Hosp Med Ctr · R01 · FY2008 · CA
Project 2: Regulation of Pre-mRNA Splicing in Tumorigenesis
$648,714Adrian R Krainer · Cold Spring Harbor Laboratory · P01 · FY2019 · CA
A longitudinal assessment of frailty in young adult survivors of childhood cancer
$648,487Kirsten Kimberlie Ness · St. Jude Children'S Research Hospital · R01 · FY2014 · CA